Huma H. Dar

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial.

The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial.

Journal: BMC medicine

Published: January 13, 2026

Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.

Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.

Journal: Journal of the National Cancer Institute

Published: October 13, 2025

Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.

Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.

Journal: International journal of cancer

Published: July 05, 2025

Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.

Progesterone receptor (PR) intra-tumor heterogeneity in premenopausal breast cancer: A secondary analysis of a randomized trial.

Journal: International journal of cancer

Published: October 25, 2024

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.

Differential long-term tamoxifen therapy benefit by menopausal status in breast cancer patients: secondary analysis of a controlled randomized clinical trial.

Journal: Journal of the National Cancer Institute

Published: May 02, 2024

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 21, 2022

Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.

Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.

Journal: JAMA network open

Published: June 30, 2021

Clinical correlation of opposing molecular signatures in head and neck squamous cell carcinoma.

Clinical correlation of opposing molecular signatures in head and neck squamous cell carcinoma.

Journal: BMC cancer

Published: June 18, 2019

Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: A cross-sectional study.

Worse quality of life in young and recently diagnosed breast cancer survivors compared with female survivors of other cancers: A cross-sectional study.

Journal: International journal of cancer

Published: April 19, 2016

Showing 1-9 of 9

Last Updated: 09/26/2026